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ABSTRACT
Background: Central serous chorioretinopathy is an idiopathic disorder that 
leads to serous neurosensory retinal detachment. The disorder is usually self-limited and 
resolves spontaneously; however, sometimes neurosensory retinal detachment persists. 
This form of the disorder is called chronic central serous chorioretinopathy (CCSC).
Objective: The aim of this study was to assess the effects of photodynamic 
therapy (PDT) on visual acuity with full-dose verteporfin for CCSC.
Methods: The eyes of patients with CCSC were included in the study. Ophthal-
mic examination including best-corrected visual acuity (BCVA), fundus examination, 
fluorescein angiography, and optical coherence tomography was performed before 
treatment and at 1, 3, 6, 9, and 12 months. PDT with full-dose verteporfin (6 mg/m2
of body surface area) was applied only to areas of active leakage. BCVA was converted to 
a log of the minimum angle of resolution (logMAR) equivalent for statistical analysis. 
Central foveal thickness and BCVA between baseline and follow-up were compared.
Results: Seventeen eyes of 16 patients (13 males, 3 females; mean [SD] age, 
39.75 [7.51] years; mean duration of follow-up, 13.06 [1.82] months) were used in the 
study. The mean (SEM) logMAR BCVA was 0.26 (0.07) at baseline and 0.04 (0.02) at 
12 months. Mean logMAR BCVA values at baseline (0.259) and after treatment 
(0.112, 0.053, 0.047, 0.041, and 0.041 at 1, 3, 6, 9, and 12 months, respectively) dif-
fered significantly (P = 0.006, P = 0.005, P = 0.005, P = 0.005, and P = 0.005). 
There was a significant difference in the mean central foveal thickness at the final visit 
(169 μm) compared with the baseline value (383 μm; P < 0.001). BCVA decreased in 
one eye (20/20 vs 20/25) and persisted during follow-up; in the other 16 eyes, BCVA 
either increased (n = 10) or remained stable (n = 6).
Conclusions: In this small, open-label study, patients with CCSC treated 
with a single course of PDT with full-dose verteporfin had significant improvement 
from baseline in BCVA and resolution of subretinal fluid accumulation and active 
leakage. Treatment was generally well tolerated, but one patient had worsening in 
BCVA. (Curr Ther Res Clin Exp. 2010;71:173 –185) © 2010 Excerpta Medica Inc.
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INTRODUCTION
Central serous chorioretinopathy (CSC) is an idiopathic disorder, first described by 
Albrecht von Graefe, that leads to serous neurosensory retinal detachment, with active 
retinal pigment epithelium leakage in the macular region.1,2 Patients with CSC typi-
cally complain of decreased visual acuity, metamorphopsia, micropsia, and a relatively 
positive scotoma caused by macular detachment. The precise pathogenesis and treat-
ment of CSC are still poorly understood. It has been reported that the acute form of 
the disorder is usually self-limited and resolves spontaneously in 4–6 months; recur-
rence occurs in about one third to one half of all patients.3–5 Good visual acuity is 
regained after spontaneous resolution of the detachment. The final visual acuity is 
better than or equivalent to 20/40 in 91% to 100% of patients who resolve 
spontaneously.3–7 Severe visual loss is reported in ~5% of patients with CSC.3,4,7
Rarely, neurosensory retinal detachment persists and leads to retinal pigment epithe-
lium and photoreceptor damage.8–10 This form of the disorder is called chronic CSC 
(CCSC) and can result in severe effects on macular function.8–11
The most common treatment for this disease is laser photocoagulation.3,12 Direct 
thermal laser photocoagulation has the disadvantages of macular photocoagulation: 
foveal distortion, scotoma, decreased contrast sensitivity, retinal pigment epitheli-
um damage, and iatrogenic choroidal neovascularization.12–16 This has led clinicians 
to investigate newer treatment modalities that might be more effective and less 
harmful. 
It has been reported that photodynamic therapy (PDT) is effective for CSC.7,17–22
Piccolino et al17 performed PDT guided by indocyanine green angiography in 16 eyes 
with CCSC. In that study, the baseline visual acuities were 20/32 to 20/400 and follow-
up was 6 to 12 months. They reported that macular exudation resolved completely in 
13 eyes (81%) and partially in 3 eyes. Moreover, visual acuity improved 1 to 4 lines in 
11 eyes and remained unchanged in 5 eyes. Yannuzzi et al18 applied PDT guided by 
indocyanine green angiography in 20 eyes of 15 patients with CCSC. In their study, 
baseline visual acuity ranged from 20/40 to 20/800 (median, 20/200; mean, 20/275). 
They observed complete resolution of exudative macular detachments in 12 patients 
and incomplete resolution in 8 eyes after treatment. Additionally, the vision improved 
in 6 eyes and remained unchanged in 14 eyes during a mean follow-up of 6.8 months. 
In a retrospective study, PDT guided by fluorescein angiography was carried out in 
9 eyes of 9 patients with acute focal retinal pigment epithelial leaks secondary to 
CSC. Baseline visual acuity ranged from 20/32 to 20/400 (median, 20/80). The au-
thors found that neurosensory detachment and fluorescein leakage resolved in all 
patients within 1 month and visual acuity improved from 1 to 6 lines in 7 eyes and 
remained unchanged in 2 eyes. There was a statistically significant improvement in 
mean visual acuity (P = 0.012), and mean visual acuity improved from 20/80 to 20/40 
at 6 months.19
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The aim of the present study was to assess the effects of PDT with full-dose verte-
porfin for the treatment of CCSC. Our study differs from earlier studies in that we 
assessed PDT with full-dose verteporfin in patients with CCSC and better baseline 
visual acuity.
PATIENTS AND METHODS
Patients
This prospective, open-label, uncontrolled observational study was conducted in 
the Department of Ophthalmology, Faculty of Medicine, Dicle University, Diyarbakir, 
Turkey. The study included the eyes of consecutive patients who were diagnosed with 
CCSC and suffered from visual problems. The diagnosis of CCSC was made when 
subretinal fluid persisted in the macular region for ≥6 months, which was determined 
by clinical examination and associated with atrophy and decompensation of the retinal 
pigment epithelium.
Inclusion criteria included active leakage upon fluorescein angiography, presence 
of subretinal fluid for ≥6 months, which involved the fovea on optical coherence to-
mography (OCT), lack of choroidal neovascularization or other disease, and 20/200 or 
better best-corrected visual acuity (BCVA). Exclusion criteria included presence of 
other maculopathy, choroidal neovascularization, or polypoid choroidal vasculopathy, 
ocular surgery or another ocular disease, history of allergy to verteporfin or fluorescein, 
and liver or kidney dysfunction. Patients who previously received PDT or laser pho-
tocoagulation for CSC or another condition were also excluded. Other exclusion crite-
ria included choroidal neovascularization or multifocal choroiditis that caused macu-
lar detachment alone or with CSC.
The experimental nature of the present study was explained to all patients before 
treatment, and written informed consent was obtained before study participation. This 
study was approved by the ethics committee of Dicle University. 
Treatment
All patients underwent a complete eye examination, including BCVA, slit lamp 
biomicroscopy, dilated fundus examination, color fundus photography, and OCT at 
baseline, and at 1, 3, 6, 9, and 12 months. Before treatment, active leakage areas were 
determined by fluorescein angiography. Fluorescein angiography was conducted at 
baseline and at 1, 3, and 12 months. To determine the presence of subretinal fluid 
accumulation and measure central foveal thickness before and after treatment at 1, 3, 
6, 9, and 12 months, OCT (OCT-3; Zeiss Humphrey, Dublin, California) was used. 
Ocular examination was performed by a single person (Y.B.S.). PDT with verteporfin 
(Visudyne, Novartis AG, Basel, Switzerland) was applied in the same manner as the 
treatment for neovascular age-related macular degeneration in the Treatment of Age-
Related Macular Degeneration with Photodynamic Therapy investigation.23 Briefly, 
verteporfin (6 mg/m2 of body surface area) was administered via intravenous infusion 
of 30 mL over 10 minutes. Fifteen minutes after the start of the infusion, a laser light 
at 689 nm delivered 50 J/cm2 at an intensity of 600 mW/cm2 over 83 seconds using 
a spot size with a diameter 1000 μm larger than the greatest linear dimension of the 
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lesion as described by fluorescein angiography. PDT was applied by laser (Visulas 
6905, Carl Zeiss Meditech AG, Jena, Germany). PDT was applied to areas of covered 
active leakage, as determined by fluorescein angiography. However, between 1000 to 
1100 μm laser spot size was used to preserve fovea in adjacent lesions. 
Repeat treatment criteria were active leakage on fluorescein angiography, together 
with the presence of subretinal fluid on OCT at 1 month after PDT. Treatment was 
not applied if there was no active leakage observed on fluorescein angiography and 
subretinal fluid accumulation on OCT, even if the patient had visual loss.
The main outcome measurements were visual acuity, central foveal thickness, and 
active areas of leakage on fluorescein angiography. Visual acuity was examined by 
Snellen testing.
Systemic adverse events (AEs) caused by verteporfin injection were monitored by 
physical examination and patient interview at each visit. Ocular AEs were monitored 
and recorded by ocular examination and patient report at each visit.
Statistical Analysis
SPSS version 11.01 (SPSS Inc., Chicago, Illinois), was used for data analysis and 
P ≤ 0.05 was considered statistically significant. Age is reported as mean (SD) and the 
other data are reported as mean (SEM) and 95% CI. To compare mean log of the 
minimum angle of resolution (logMAR) BCVA values and central foveal thickness, 
a nonparametric Wilcoxon-signed rank test and paired-sample t test were used, re-
spectively. Visual acuity scores were converted to the logMAR by using a table of 
equivalent visual acuities for statistical analysis.24
RESULTS
Sixteen consecutive patients (males, 13 [81.3%]; mean [SD] age, 39.75 [7.51] years; 
median age, 39 years [range, 29–56 years]) with 17 eyes diagnosed with CCSC were 
approached for enrollment in the study; none were excluded. All 16 patients completed 
the 12-month follow-up. Three of the 16 patients had a history of steroid usage before 
presentation; steroid use was stopped ≥6 months before treatment. The mean duration 
of follow-up was 13.06 (1.82) months. Baseline BCVA values ranged from 20/200 to 
20/20. Table I summarizes the clinical features of the patients and Table II summarizes 
treatment results.
The active leakage areas were closed within the first month after treatment in all 
patients, and no recurrence was seen during follow-up (Figure 1). PDT was applied 
only once in all patients and none required a second treatment during follow-up. 
The mean (SEM) central foveal thickness was 383.35 (29.61) μm at baseline, and 
237.82 (18.9), 188.82 (10.66), 172.24 (5.38), 169.76 (5.1), and 169.24 (5.04) μm at 1, 
3, 6, 9, and 12 months, respectively (Figure 2). The mean central foveal thickness at all 
postbaseline visits was significantly less than that at baseline (all, P < 0.001). There was 
a significant difference in mean central foveal thickness at the final visit compared with 
the pretreatment value (P < 0.001). Moreover, there was a significant difference in mean 
central foveal thickness between 1 month and 3 months, 1 month and 6 months, and 
3 and 6 months (P = 0.006, P = 0.001, and P = 0.01, respectively).
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The baseline BCVA was 20/20 in 7 of 17 eyes (41.18%). However, these patients 
had complaints such as metamorphopsia, relative scotoma, or micropsia, and there was 
subretinal fluid accumulation on OCT. One patient (patient 16) had bilateral CCSC, 
whereas the other patients had unilateral CCSC. Patient 16 had 1 active leakage area 
in his right eye and 2 active leakage areas in his left eye (Figures 3 and 4). PDT was 
applied to both leakage areas in the left eye and to the single leakage area in the right 
eye. The other patients had only one leakage area in each eye. 
The mean (SEM) logMAR BCVA was 0.26 (0.07) at baseline, 0.11 (0.05) at 1 month, 
0.05 (0.03) at 3 and 6 months, and 0.04 (0.02) at 9 and 12 months (Figure 5). BCVA 
values after treatment were significantly lower (P = 0.006, P = 0.005, P = 0.005, 
P = 0.005, and P = 0.005 at 1, 3, 6, 9, and 12 months, respectively). There were no 
significant differences in BCVA values in follow-up after the third month. There was 
a significant difference between month 1 and month 3 (P = 0.041). Visual acuity was 
Table I.  Clinical characteristics of study patients with chronic central serous chorioreti- 
nopathy (CCSC) (N = 16). 
Case Age, y Sex Eye
Eye 
Color
Duration 
of CCSC, 
mo
Treated 
Areas, 
no.
PDT spot 
size, μm
 1 56 M Right Brown 8 1 1050
 2 42 F Left Brown 9 1 1100
 3 41 M Right Green 12 1 1000
 4 34 M Left Brown 8 1 1050
 5 43 M Right Brown 6 1 1150
 6 55 F Left Brown 7 1 2700
 7 30 M Left Brown 9 1 1250
 8 37 M Right Brown 12 1 2150
 9 38 M Right Green 7 1 1900
10 44 M Right Brown 10 1 1700
11 37 M Left Brown 6 1 1650
12 37 M Right Brown 6 1 1200
13 40 F Left Brown 6 1 1800
14 29 M Left Brown 6 1 1100
15 40 M Right Brown 8 1 2000
16 33 M Right Brown 10 1 2900
Left Brown 10 2 2750 and 
1500
PDT = photodynamic therapy; M = male; F = female.
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decreased in the first month (20/20 vs 20/25) after treatment in 1 patient (patient 16) 
and persisted during follow-up.
After the first month, secondary retinal pigment epithelium changes were observed 
in areas where PDT was applied, but there was no choroidal neovascularization. No 
patients reported systemic adverse effects related or not related to treatment. 
DISCUSSION
PDT has been used for secondary choroidal neovascularization caused by age-related 
macular degeneration.23 Studies have reported the effectiveness of PDT for 
CCSC.7,17,18,21,22 The exact mechanism of PDT in treating CCSC has not been fully 
established, but it is thought to be caused by short-term choriocapillary hypoper- 
fusion and long-term choroidal vascular remodeling, which leads to reduction in 
choroidal congestion, vascular hyperpermeability, and extravascular leakage.22,25,26
Retinal pigment epithelium cells damaged by light-activated verteporfin might be 
Table II.  The results of photodynamic therapy with verteporfin in patients with chronic 
central serous chorioretinopathy (N = 16).
BCVA CFT, μm
Patient Pretreatment Posttreatment Pretreatment Posttreatment
 1 20/32 20/20 368 182
 2 20/40 20/20 473 170
 3 20/20 20/20 381 176
 4 20/20 20/20 216 173
 5 20/20 20/20 340 171
 6 20/200 20/25 570 200
 7 20/63 20/20 645 159
 8 20/20 20/20 194 153
 9 20/40 20/20 223 150
10 20/63 20/20 383 205
11 20/25 20/20 290 157
12 20/50 20/20 344 191
13 20/50 20/25 424 159
14 20/20 20/20 415 155
15 20/20 20/20 308 194
16 20/100 20/50 497 124
20/20 20/25 446 158
BCVA = best-corrected visual acuity; CFT = central foveal thickness.
179
Y.B. Sakalar et al.
replaced by new ones, with possible recovery from metabolic impairment at the retinal 
pigment epithelium level.21 Previous studies also have reported that damage induced 
by PDT with verteporfin is not confined to the endothelium of choroidal neovasculariza-
tion, but also affects the endothelium of the choriocapillaries.27,28
In some previous studies of CCSC, PDT has been found to be effective and visual 
acuity in almost all cases has increased or remained stable.7,17,18,21,22 In the present 
study, visual acuity after PDT with full-dose verteporfin increased in 10 of 17 eyes and 
remained stable in 6. Visual acuity in the left eye of patient 16, in which both eyes 
were treated with PDT, decreased from 20/20 to 20/25 at 1 month after treatment, 
and remained at this level for the duration of follow-up. There was leakage at 2 dif-
ferent areas in this eye, and 2 nonadjacent laser spots of 2750 and 1500 μm were used. 
In earlier studies,7,17,18,21,22 decreases in vision without choroidal neovascularization 
secondary to PDT were not reported after PDT with full-dose verteporfin. Colucciello29
reported the occurrence of loss of visual acuity and choroidal neovascularization after 
A B
C D
E
Figure 1.  Patient 1 of 16 patients with chronic central serous chorioretinopathy treated 
with photodynamic therapy (PDT) and verteporfin. (A) Fundus photography be-
fore PDT. (B) Active leakage as seen by fluorescein angiography before PDT. (C) 
Closure of leakage and retinal pigment epithelium changes at 1 month after 
PDT. (D) Subretinal fluid accumulation before treatment, as seen by optical 
coherence tomography (OCT). (E) Complete resolution of subretinal fluid, as 
seen by OCT at 1-month follow-up.
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PDT with full-dose verteporfin for CCSC, which might have occurred as a result 
of choroidal hypoperfusion. Piccolino et al17 reported that multiple adjacent laser 
applications can lead to hyper-dosage effects. Adjacent laser applications might en-
hance the ischemic effect of a singular irradiation and make reperfusion more difficult 
in certain areas of the choriocapillaris. Wang et al30 found that foveal atrophy in CSC 
is associated with reduced visual acuity, despite resolution of the serous detachment. 
They suggested that foveal attenuation in CSC was associated with >4 months’ duration 
of symptoms and persistent BCVA reduction despite resolution of the serous detach-
ment. These potential adverse effects need further evaluation and might be important 
considerations for restricting the extensive use of PDT for CCSC until more data is 
available.
In the present study, in all cases, including the patient with visual acuity decrease, 
subretinal fluid was resolved in the first month and no recurrence was seen at follow-up. 
In earlier studies also, subretinal fluid was reported to have been resolved partially or 
completely after PDT.7,17,18,21,22 In one of these studies, subretinal fluid was resolved 
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Figure 2.  Changes in mean central foveal thickness before treatment (baseline) and at 
follow-up in patients with chronic central serous chorioretinopathy treated with 
photodynamic therapy and verteporfin. *P < 0.001 versus baseline; †P = 0.006 
versus month 1; ‡P = 0.001 versus month 1; §P = 0.001 versus month 3.
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completely in all cases.7 The resolution of subretinal fluid might be associated with re-
modeling of the choriocapillaris and absorption of subretinal fluid by intact retinal pig-
ment epithelium cells.17 Piccolino et al17 reported that these lasting effects of PDT in 
the prevention of subretinal exudation might be correlated with hypoperfusion induced 
in the choriocapillaris. A study by Yannuzzi et al18 reported that 2 eyes experienced 
recurrent macular detachments at 4 months after treatment, despite previous resolution 
of the detachments. Similarly, recurrence was experienced in 2 eyes in the studies by 
Piccolino et al. However, recurrence was not observed in the study carried out by 
Taban et al.7 In the study by Taban et al, 5 eyes of 4 patients with CCSC were adminis-
tered PDT with full-dose verteporfin and patients were followed for an average of 
10 months. In all of the present study’s cases, retinal pigment epithelium changes oc-
curred after the first month in the area where PDT was applied, and these changes re-
mained for 12 months. These retinal pigment epithelium changes after PDT might have 
been caused by choroidal hypoperfusion in areas where PDT was applied. In CSC, an-
other secondary complication of PDT is choroidal neovascularization.20,29 In the present 
study, choroidal neovascularization associated with PDT did not develop in any of the 
patients. In addition, there were no systemic adverse effects associated with verteporfin.
A B
C D
Figure 3.  Right eye of patient 16 of 16 patients with chronic central serous chorioretin-
opathy treated with photodynamic therapy (PDT) and verteporfin. (A) Area 
of active leakage, as seen by fluorescein angiography before PDT. (B) Closure 
of active leakage after PDT, as seen by fluorescein angiography at 1 month. 
(C) Subretinal fluid and macular detachment, as seen by optical coherence 
tomography (OCT). (D) Complete resolution of subretinal fluid at 1 month after 
treatment, as seen by OCT.
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Our study has several limitations, such as the absence of a control group, the open-
label design, small number of patients, and relatively short period of follow-up. The 
baseline visual acuity of our patients was also better than that in previous studies.17–19
In this study, no patients required a second application of PDT. This suggests that a 
single application of PDT might be sufficient for treatment of some cases of CCSC. 
The present study included 13 months of follow-up. Although this is a relatively short 
period, it might have been sufficient for assessment of the results. Further studies are 
needed to determine the efficacy and tolerability of PDT with full-dose verteporfin for 
treatment of CCSC.
CONCLUSIONS
In this small, open-label study, patients with CCSC treated with a single course of 
PDT with full-dose verteporfin had significant improvement from baseline in BCVA 
and resolution of subretinal fluid accumulation and active leakage. Treatment was 
generally well tolerated, but one patient had worsening of BCVA after treatment.
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Figure 4.  Left eye of patient 16 of 16 patients with chronic central serous chorioretinopa-
thy treated with photodynamic therapy (PDT) and verteporfin. (A) Two areas of 
active leakage, as seen by fluorescein angiography before PDT. (B) Closure of 
leakage and retinal pigment epithelium changes after PDT. (C) Subretinal fluid 
before treatment, as seen by optical coherence tomography (OCT). (D) Resolu-
tion of subretinal fluid, as seen by OCT at 1 month after treatment.
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